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Extracellular Calreticulin Is Present in the Joints of
Patients With Rheumatoid Arthritis and
Inhibits FasL (CD95L)–Mediated Apoptosis of T Cells
Joanna M. Tarr,1 Paul G. Winyard,1 Brent Ryan,1 Lorna W. Harries,1 Richard Haigh,2
Nick Viner,3 and Paul Eggleton1
Objective. The binding of FasL (CD95L) to its
receptor, Fas (CD95), induces apoptosis. Studies have
shown that in patients with rheumatoid arthritis (RA),
T lymphocytes are resistant to FasL-induced apoptosis
in vivo but are susceptible to FasL-induced apoptosis in
vitro. Dysfunction in this mechanism may be an impor-
tant contributor to the pathophysiology of RA. Thus, the
present study was undertaken to determine which fac-
tors might inhibit FasL–Fas binding in vivo and those
that would inhibit apoptosis of T lymphocytes in an in
vitro model system.
Methods. Human Jurkat T cells rendered apopto-
tic by FasL exposure were analyzed by flow cytometry.
Necrosis was determined according to measurement of
lactate dehydrogenase release. Quantification of calre-
ticulin in plasma and synovial fluid and of calreticulin–
FasL binding was performed by enzyme-linked immu-
nosorbent assay. Measurement of nitrite/nitrate in the
plasma and synovial fluid was carried out by chemilu-
minescence assay.
Results. Extracellular calreticulin was present at
a significantly higher concentration in the plasma (me-
dian 10.3 ng/ml, interquartile range [IQR] 14.8 ng/ml)
and synovial fluid (median 10.3 ng/ml, IQR 12.0 ng/ml)
of RA patients (each P < 0.05) compared with the
plasma (median 3.1 ng/ml, IQR 1.3 ng/ml) and synovial
fluid (median 2.9 ng/ml, IQR 0.9 ng/ml) of patients with
psoriatic arthritis and the plasma of healthy control
subjects (median 2.9 ng/ml, IQR 0.9 ng/ml). Calreticulin
concentrations in the synovial fluid correlated with the
tender and swollen joint counts and the activity scores
on the 28-joint Disease Activity Score assessment. Cal-
reticulin also bound directly to FasL. In vitro, calreti-
culin (2–16 ng/ml) inhibited FasL-induced apoptosis of
Jurkat T cells.
Conclusion. Calreticulin was present at higher
concentrations in the plasma and synovial fluid of RA
patients. Calreticulin had the capacity to bind directly
to FasL and to inhibit FasL-mediated apoptosis of
Jurkat T cells, and thus might play a role in inhibiting
apoptosis of inflammatory T cells in RA.
Rheumatoid arthritis (RA) is characterized by
the accumulation of leukocytes in the synovial compart-
ments of the joints. T lymphocytes infiltrate the joint
space and are known to be resistant to apoptosis (1). The
ability of autoreactive T cells to undergo apoptosis is of
great importance in the maintenance of tissue ho-
meostasis in the joints. Synovial T cells appear to be
highly differentiated and are susceptible to apoptosis in
vitro, but appear to evade cell death in vivo. Studying the
regulation of T cell apoptosis is important in under-
standing the mechanism of joint destruction observed in
RA.
A number of studies have investigated the apo-
ptotic regulatory systems of synovial T cells from the
joints of RA patients (2,3), and results have suggested
Supported by a Peninsula College of Medicine and Dentistry
Studentship and an Arthritis Research UK PhD Studentship (17966),
to Drs. Winyard and Eggleton.
1Joanna M. Tarr, PhD, Paul G. Winyard, PhD, Brent Ryan,
BSc (Hons), Lorna W. Harries, PhD, Paul Eggleton, MPhil, PhD:
Peninsula College of Medicine and Dentistry, and University of
Exeter, Exeter, UK; 2Richard Haigh, MRCP: Peninsula College of
Medicine and Dentistry, University of Exeter, and Royal Devon and
Exeter Foundation Trust Hospital, Exeter, UK; 3Nick Viner, PhD,
FRCP: Peninsula College of Medicine and Dentistry, and University
of Exeter, Exeter, and Torbay Hospital, Torquay, UK.
Dr. Haigh has received speaking fees from UCB and Roche
(less than $10,000 each).
Address correspondence and reprint requests to Paul Eggle-
ton, MPhil, PhD, University of Exeter, St. Luke’s Campus, Heavitree
Road, Exeter, Devon EX1 2LU, UK. E-mail: paul.eggleton@
pms.ac.uk.
Submitted for publication August 6, 2009; accepted in revised
form June 3, 2010.
2919
that dysregulation of the survival protein Bcl-2 in either
T cells or synovial cells may be implicated in T cell
survival (4). Others have focused on interference of the
apoptotic process mediated by the Fas antigen, which is
expressed on 40–60% of CD3 T cells in the synovium
(5). There is a consensus that the Fas signaling pathway
is involved in defective T cell (6) and synovial cell (7)
apoptosis. The majority of studies have been performed
on synovial cells, and these cells become resistant to
apoptosis upon exposure to transforming growth factor
1 or may become resistant depending on differences in
cell cycle components (8). Despite the Fas/FasL system
being implicated in the pathogenesis of RA, there is
surprisingly little information on factors present in the
plasma or synovial fluid of patients with RA that might
inhibit this important mechanism of apoptosis.
It has been shown that the intracellular chaper-
one calreticulin can be secreted from cells (9) and can
bind directly to FasL in vitro (10). Further evidence of
the presence of extracellular calreticulin comes from a
number of studies in autoimmune diseases in which
autoantibodies against calreticulin have been detected
(11–13). Of note, calreticulin was recently identified as
an autoantigen in patients with RA (14), although the
plasma concentration of calreticulin itself has never
been measured. We have previously shown that calreti-
culin can bind to a number of other immune-regulatory
proteins, e.g., the first component of complement C1q,
and such interaction impedes the ability of C1q to bind
to immune complexes and activate the classical comple-
ment pathway (15,16). Furthermore, Ling et al (17)
demonstrated that a shared epitope (consisting of a
5–amino acid sequence motif in position 70–74 of the
hypervariable region of the HLA–DR -chain, detected
on lymphocytes present in the majority of RA patients)
acts as a trigger for the production of the proinflamma-
tory reactive oxygen species nitric oxide (NO), and that
cell surface calreticulin plays a critical role in shared
epitope signal transduction (18). In addition, in some
cell systems, overexpression of calreticulin activates ni-
tric oxide synthases, which thereby increases NO pro-
duction (19).
Thus, we investigated the ability of calreticulin to
inhibit Fas/FasL-dependent T cell apoptosis and deter-
mined whether plasma/synovial fluid calreticulin con-
centrations are correlated with disease activity. Because
T cells isolated from the synovial fluid of RA patients
are predominantly resistant to FasL-mediated cell
death, Jurkat T cells were chosen as a model cell. Jurkat
cells share many phenotypic similarities with synovial T
cells but are not resistant to FasL-induced cell death. We
wished to exploit this difference to determine whether
components found in the synovial fluid of RA patients
could induce T cell–like resistance to FasL-mediated
apoptosis. Finally, we explored the possibility that extra-
cellular calreticulin plays a role in the production and
release of NO from cells, since NO has been implicated
in the modulation of T cell apoptosis (20).
PATIENTS AND METHODS
Antibodies and reagents. Mouse monoclonal antibod-
ies (mAb) against human calreticulin were purchased from
Cambridge Biosciences, while rabbit polyclonal antibodies
against human calreticulin were developed as previously de-
scribed (21). Horseradish peroxidase (HRP)–conjugated goat
anti-mouse antibodies and HRP-conjugated goat anti-rabbit
antibodies were obtained from Santa Cruz Biotechnology. A
rabbit polyclonal anti-FasL antibody (ab15285) was obtained
from Abcam. The enzyme-linked immunosorbent assay
(ELISA) substrate 3,3,5,5-tetramethylbenzidine (TMB) was
bought from Bio-Rad. Nunc Maxisorp 96-well plates and
Amicon centrifugal concentrators were purchased from Fisher
Scientific UK. Cayman Chemical cytotoxicity assays for the
detection of lactate dehydrogenase (LDH) activity and soluble
FasL were purchased from Enzo Life Sciences. Sulfuric acid
was purchased from Sigma-Aldrich UK. Slide-a-lysers were
purchased from Perbio Science UK. S-Monovette EDTA K2
and lithium heparin tubes were purchased from Sarstedt.
Native human calreticulin was purified from Jurkat cells using
a method as previously described (22) or prepared in a
recombinant form as previously reported (23).
Patients and samples. Plasma and synovial fluid sam-
ples were obtained from 32 patients with RA (28 female and 4
male; mean age 59.6 years, range 24–82 years) and from 7
patients with psoriatic arthritis (PsA) (mean age 33.3 years,
range 19–54 years), and plasma samples were obtained from 30
patients with systemic lupus erythematosus (SLE) (28 female
and 2 male; mean age 56.9 years, range 30–73 years) and from
27 healthy control subjects (21 female and 6 male; mean age
43.7 years, range 24–69 years). Peripheral blood samples were
stored in S-Monovette EDTA tubes, and plasma was collected.
All patients with RA fulfilled the American College of Rheu-
matology (ACR; formerly, the American Rheumatism Associ-
ation) 1987 criteria for RA (24), all patients with SLE fulfilled
the ACR 1982 criteria for SLE (25), and patients with PsA
fulfilled the criteria of Moll and Wright (26). Local ethics
approval was provided for all experiments, and informed
consent was obtained from all study subjects (Multicenter
Research Ethics Committee project number 06/Q2102/56 and
Local Research Ethics Committee number 04/Q2102/87).
Cells. Jurkat T cells were grown in RPMI 1640 supple-
mented with 90 units/ml of penicillin, 90 g/ml streptomycin, 2
mM L-glutamine, and 10% volume/volume heat-inactivated
fetal bovine serum at 37°C in an atmosphere of 5% CO2.
Jurkat cells were chosen for use in a model of CD95/CD95L-
mediated apoptosis, since previous studies have shown that
between 80% and 100% of synovial fluid T cells and Jurkat
cells express CD95, compared with only 40% of peripheral
blood lymphocytes (27,28). Synovial fluid T cells and Jurkat
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cells also have similar surface expression of integrins (29). In
contrast, synovial T cells differ from Jurkat cells in their
resistance to FasL-induced cell death (30).
Analysis of apoptotic genes in RA patients, SLE pa-
tients, and healthy subjects using quantitative reverse
transcription–polymerase chain reaction (RT-PCR). The Fas
apoptosis gene family, consisting of the genes encoding Fas,
FasLG, FADD, CFLAR, CASP8AP2, and LRDD, was
screened using quantitative RT-PCR TaqMan apoptotic tiled
low density gene array (TLDA) (part no. 4378701; Applied
Biosystems). Initially, RNA was isolated from 5  106 lympho-
cytes from all subjects using an RNeasy mini kit, and the RNA
was then supplemented with 10 l RNA stabilization reagent
(Qiagen). Complementary DNA (cDNA) was reverse tran-
scribed from 500 ng of total isolated RNA from 5 patients with
RA, 7 patients with SLE, and 7 healthy controls, using the
TaqMan Reverse Transcription kit (Applied Biosystems) in a
total volume of 50 l. Reaction mixtures for each sample
contained 200 l TaqMan Universal PCR Master Mix with 40
l cDNA (corresponding to 400 ng RNA) in a total volume of
400 l. The reaction mixture (4  100 l) was then added to
each loading port on the array, and 2 samples were analyzed
per plate. Amplification conditions were as follows: 2 minutes
at 50°C to activate uracil N-glycosylase, 10 minutes at 94.5°C
(for activation), 40 cycles of denaturation at 97°C for 30
seconds, and annealing and extension at 59.7°C for 1 minute.
Sample measurements were performed in duplicate on the
same TLDA run. Data were analyzed using the comparative
threshold cycle (Ct) method using relative quantification
software (SDS2.2; Applied Biosystems), and gene expression
in the samples was quantified relative to the levels of 3
housekeeping genes, 18S, ACTB (for -actin), and GAPDH.
Quality control was achieved by comparison of the duplicate
crossing points for each gene in each sample.
Measurement of calreticulin, nitrite/nitrate, and LDH
in plasma and synovial fluid. The concentration of calreticulin
in plasma and synovial fluid was quantified with the use of a
sandwich ELISA. Briefly, 96-well Nunc Maxisorp plates were
coated with 100 l of rabbit polyclonal anticalreticulin IgG (2.1
mg/ml) at a 1:3,000 dilution in sodium carbonate buffer, pH
7.4, and the plate was left to incubate overnight at 4°C. Wells
were then washed twice with phosphate buffered saline (PBS)
containing 0.05% v/v Tween (PBST) and then twice with PBS
to remove unbound polyclonal anticalreticulin. Residual bind-
ing sites were blocked with 5% weight/volume milk powder
(Marvel) in PBST for 2 hours at 37°C. Wells were washed twice
with PBST and twice with PBS. A standard curve of 100-l
aliquots of known concentrations of recombinant calreticulin
diluted in 5% w/v milk/PBST was run on each plate. Plasma or
synovial fluid samples were diluted 1:10 in milk/PBST, and
triplicate 100-l samples were added to the wells. The plates
were incubated for 90 minutes at 37°C, and then washed as
described above.
Calreticulin binding was detected using an mAb
against calreticulin (Cambridge Biosciences) in a dilution of
1:2,000 in milk/PBST, followed by incubation for 2 hours at
37°C. The wells were washed as described above, and a
secondary HRP-conjugated goat anti-mouse IgG (Santa Cruz
Biotechnology) was added to 100-l aliquots, diluted 1:2,000 in
milk/PBST, and incubated for 1 hour at 37°C. The wells were
washed as described above, and 100 l TMB/well was added.
The reaction was developed for 30 minutes at room tempera-
ture in the dark and was then terminated by adding 50 l of 2N
H2SO4 to each well. The plates were assessed by ELISA on a
BMG Labtech FLUROstar plate reader at 450 nm.
Nitrite and nitrate measurements were performed in
the plasma from healthy control volunteers and patients with
SLE and in the plasma and synovial fluid samples from
patients with RA. Before the samples were analyzed for nitrite
and nitrate concentrations, they were deproteinized using zinc
sulfate precipitation (31). This was performed by adding 200 l
ultrapure water and 300 l 0.3M NaOH to 100 l plasma or
synovial fluid samples, followed by incubation at room tem-
perature for 5 minutes. Zinc sulfate solution (300 l, 5% w/v)
was added to the mixture, followed by incubation for 10
minutes at room temperature. Each sample was centrifuged at
10,000g for 15 minutes, and the supernatant was analyzed for
nitrite and nitrate using a Sievers nitric oxide analyzer (Sievers
NOA 280; Analytix) according to the method described previ-
ously (32). Briefly, samples were refluxed in either 0.1M
vanadium III chloride and 1M HCl at 95°C (for nitrate
analysis) or in 0.3M sodium iodide and glacial acetic acid at
room temperature (for nitrite analysis). These conditions
reduce both nitrate and nitrite to NO. The NO reacts with
ozone, causing light emission, which is detected and measured
by chemiluminescence assay. To determine the concentrations
of nitrite and nitrate in the samples, standard curves were
created using known concentrations of NaNO2 or NaNO3.
Throughout the sample measurements, known standards were
periodically injected to determine the efficiency of the reduc-
tion reaction. Samples were analyzed in triplicate.
LDH is a marker enzyme for cell membrane integrity,
since it is present in the cytosol of cells and is released during
cell lysis and necrosis. A Cayman Chemical LDH assay was
used to measure the activity of LDH present in the plasma and
synovial fluid samples. The assay was performed according to
the manufacturer’s protocol.
Generation of apoptotic cells. Jurkat T cells were
incubated in 96-well plates with FasL for 4 hours in a humid-
ified atmosphere of 5% CO2 at 37°C. A concentration of FasL
of 0.78 nM and an incubation period of 4 hours were chosen
because these conditions have been shown, in preliminary
work for this study, to induce 30% apoptosis. After incuba-
tion, the cells were assessed for apoptosis using annexin V and
7-aminoactinomycin D (7-AAD) staining and a Beckman
Coulter Quanta SC flow cytometer and Cell Lab Quanta
software. Early apoptotic cells stained positive with annexin V
alone and late apoptotic cells stained positive with annexin V
and 7-AAD, while necrotic cells only stained positive with
7-AAD.
Analysis of FasL binding to calreticulin. Aliquots (100
l) of native calreticulin (10 g/ml) in NaCO3 buffer (pH 9.6)
were added to each individual well of a 96-well Nunc Maxisorp
plate. The plate was incubated overnight at 4°C and then
washed with PBST. Unoccupied absorption sites were blocked
with 3% w/v bovine serum albumin (BSA) in PBST for 1 hour
at 37°C. The plates were then washed as described above.
Aliquots (100 l) of either 0, 1, or 2 g/ml FasL diluted in 3%
w/v BSA in PBST were added to triplicate wells and incubated
for 1 hour at 37°C. The plates were again washed as described
above.
FasL binding to calreticulin was detected by adding to
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each well 100 l of rabbit polyclonal anti-FasL antibody (1
g/ml diluted in 3% w/v BSA in PBST; Abcam) and incubating
the plates for 1 hour at 37°C. The wells were washed as
described before, and 100-l aliquots of HRP-conjugated goat
anti-rabbit antibody (Santa Cruz Biotechnology) at a 1:2,000
dilution in 3% BSA in PBST were added to each well. The
plates were then incubated at 37°C for 1 hour. The plates were
washed in PBST, and 100 l TMB/well was added and
developed for 30 minutes at room temperature in the dark.
Each reaction was terminated by adding 50 l of 2N H2SO4,
and the plates were read on an ELISA plate reader at 450 nm.
Assessment of the ability of calreticulin to inhibit
FasL-mediated apoptosis. To determine whether the binding
of calreticulin to FasL inhibited FasL-induced apoptosis, cal-
reticulin and FasL were preincubated together for 1 hour at
room temperature, after which the coincubated proteins were
added to cultures with Jurkat cells. The effect of calreticulin
and FasL on early and late-stage apoptosis was assessed by
staining with fluorescein isothiocyanate–annexin V and
7-AAD (15 minutes at 4°C). Inhibition of apoptosis was
performed in 96-well plates into which varying concentrations
of calreticulin (0, 1, 2, 4, 8, and 16 g/ml) were added alone or
in combination with 0.78 nM FasL, followed by incubation for
1 hour at room temperature. Jurkat cells (1  106 cells/ml)
were then added to each well to a final volume of 250 l. The
Jurkat cells were then incubated for a further 4 hours in a
humidified atmosphere with 5% v/v CO2 at 37°C.
After incubation, the cells were removed from the
96-well plates and assessed for apoptosis by flow cytometry. To
assess the ability of calreticulin to specifically inhibit FasL-
mediated apoptosis, inhibition of calreticulin binding to FasL
by the anticalreticulin antibody (0–25 nM) was conducted by
coincubating calreticulin with anticalreticulin for 1 hour at
room temperature, followed by incubation with 0.78 nM FasL
for 1 hour at room temperature. The proteins were then added
to cultures with Jurkat cells (1  106 cells/ml), followed by
incubation for 4 hours in the same manner as outlined above.
Statistical analysis. Data were checked for normality.
Data that were not normally distributed were analyzed using
the Mann-Whitney U test and Wilcoxon’s signed rank test for
statistical comparison of unpaired and paired samples, respec-
tively. Statistical correlation was assessed using Spearman’s
rank correlation coefficients. A probability level set at P values
less than 0.05 was chosen as the threshold for statistically
significant differences between groups, as determined by the
Mann-Whitney U test, Wilcoxon’s signed rank test, and Spear-
man’s rank correlation analysis. The statistical significance of
differential gene expression determined on TLDA in samples
from normal, RA, and SLE subjects was determined by
Mann-Whitney U test using pairwise comparisons of individual
Ct measurements (RA patients compared with controls and
SLE patients compared with controls) for each sample group.
The threshold for significance was set at P values less than or
equal to 0.05.
RESULTS
Expression of Fas signaling genes. To ascertain
whether the decreased expression of Fas and associated
apoptosis family genes might be responsible for the lack
of Fas-induced apoptosis that has been observed in RA
patients, quantitative RT-PCR was performed. The ex-
pression levels of Fas, FasLG, FADD, CFLAR,
CASP8AP2, and LRDD were not significantly different
in lymphocytes from patients with RA compared with
those from patients with SLE and healthy controls
(Figure 1).
Concentrations of calreticulin and LDH in
plasma and synovial fluid samples from patients. The
median concentrations of calreticulin in the plasma and
synovial fluid of patients with RA (median 10.3 ng/ml,
interquartile range [IQR] 14.8 ng/ml and median 10.3
ng/ml, IQR 12.0 ng/ml, respectively) were significantly
higher (P 0.05) compared with the median calreticulin
concentrations in the plasma of healthy controls (me-
dian 2.9 ng/ml, IQR 0.9 ng/ml), plasma of patients with
SLE (median 2.8 ng/ml, IQR 2.6 ng/ml), and plasma and
synovial fluid of patients with PsA (median 3.1 ng/ml,
IQR 1.3 ng/ml and median 2.9 ng/ml, IQR 0.9 ng/ml,
respectively) (Figure 2).
Measurements of LDH activity in the samples
were performed in order to ascertain whether the calre-
ticulin detected in the RA patients’ plasma and synovial
fluid was released as a result of necrosis of the cells.
There was a significant increase in LDH activity in the
plasma and synovial fluid of RA patients (median 0.12
arbitrary units [AU]/minute, IQR 0.08 AU/minute and
median 0.18 AU/minute, IQR 0.12 AU/minute, respec-
tively) compared with that in the plasma of healthy
controls (median 0.09 AU/minute, IQR 0.06 AU/
minute), plasma of patients with SLE (median 0.11
Figure 1. The expression of Fas signaling genes in peripheral blood
lymphocytes from patients with rheumatoid arthritis (RA) (n  5),
patients with systemic lupus erythematosus (SLE) (n 7), and healthy
control subjects (n  7), as determined by quantitative reverse
transcription–polymerase chain reaction. Results are presented as the
mean and SD fold change relative to 3 housekeeping genes.
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AU/minute, IQR 0.06 AU/minute), and plasma and
synovial fluid of patients with PsA (median 0.11 AU/
minute, IQR 0.09 AU/minute and median 0.12 AU/
minute, IQR 0.06 AU/minute, respectively) (Figure 3).
Moreover, a statistically significant increase in the me-
dian LDH activity in the plasma as compared with the
synovial fluid of patients with RA was also observed.
These data indicate that in the RA patients’ plasma, cell
necrosis was occurring, and even more necrosis was
occurring in the synovial fluid of RA patients.
Analyses of correlations between the calreticulin
concentrations and LDH activity in RA patients’ plasma
and synovial fluid were performed to assess whether
calreticulin was being released from necrotic cells. There
was no significant correlation (P  0.05) between the
calreticulin concentrations and LDH levels in the RA
patients’ plasma or synovial fluid (results not shown).
These data indicate that calreticulin was not predomi-
nantly released from the cells into the RA patients’
plasma or synovial fluid by necrosis.
Correlation of plasma and synovial fluid calreti-
culin levels with RA disease activity. Calreticulin con-
centrations in RA plasma and synovial fluid were corre-
lated with disease activity. Spearman’s rank correlation
analyses were performed to assess correlations between
the concentrations of calreticulin in RA patients’ plasma
and synovial fluid and the swollen and tender joint
counts and Disease Activity Score in 28 joints (DAS28)
(33) (Figure 4). A significant correlation was observed
between calreticulin concentrations in the synovial fluid
and the tender joint counts (rs  0.373, P  0.04),
swollen joint counts (rs  0.370, P  0.04), and DAS28
(rs  0.440, P  0.02). The correlation between calreti-
culin concentrations and the DAS28 in RA patients was
also significant in the plasma (rs  0.439, P  0.02), but
the correlations between plasma calreticulin concentra-
tions and the tender joint and swollen joint counts did
not reach statistical significance (rs  0.342, P  0.06
and rs  0.344, P  0.06, respectively). A Bonferroni
correction for multiple comparisons was not performed,
because this study was focused only on the relationship of
joint inflammation and mobility with calreticulin levels,
and the mathematical correction is not recommended for a
limited number of related comparisons (34).
Concentrations of nitrite and nitrate in plasma
and synovial fluid samples from patients. Measure-
ments of nitrite and nitrate were performed on the
patients’ samples as an indirect assessment of the gen-
Figure 3. Activity of lactate dehydrogenase (LDH) in autoimmune
diseases. Extracellular LDH activity was assessed by colorimetric assay in
plasma from healthy control subjects (n 27), plasma from patients with
SLE (n  30), and matched plasma and synovial fluid samples from
patients with RA (n  32) and patients with PsA (n  7). Bars show the
median and interquartile range. See Figure 2 for other definitions.
Figure 2. Concentrations of calreticulin (CRT) in autoimmune dis-
eases. A sandwich enzyme-linked immunosorbent assay was used to
measure the concentration of calreticulin in plasma from healthy
control (HC) subjects (n  27), plasma from patients with systemic
lupus erythematosus (SLE) (n  30), and matched plasma and
synovial fluid (SF) samples from patients with rheumatoid arthritis
(RA) (n  32) and patients with psoriatic arthritis (PsA) (n  7). Bars
show the median and interquartile range.  P 0.05 versus all other
groups.
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Figure 4. Correlations between calreticulin concentrations in the plasma (A, C, and E) and
synovial fluid (B, D, and F) of patients with RA and the level of disease activity. The disease activity
was measured by assessing the tender joint count (A and B), the swollen joint count (C and D), and
the 28-joint Disease Activity Score (DAS28) (E and F). Correlations with the calreticulin
concentration, as determined by Spearman’s rank correlation coefficient analyses, were as follows:
for plasma calreticulin and tender joint count, rs  0.342, P  0.059 (A); for synovial fluid
calreticulin and tender joint count, rs  0.373, P  0.039 (B); for plasma calreticulin and swollen
joint count, rs  0.344, P  0.058 (C); for synovial fluid calreticulin and swollen joint count, rs 
0.370, P 0.040 (D); for plasma calreticulin and DAS28, rs 0.439, P 0.017 (E); and for synovial
fluid calreticulin and DAS28, rs  0.440, P  0.017 (F). See Figure 2 for other definitions.
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eration of NO. There was a statistically significant
increase in the concentration of nitrite in RA plasma
(median 0.99 M, IQR 0.72) and RA synovial fluid
(median 1.25 M, IQR 0.89) as compared with that in
the plasma from healthy controls (median 0.74 M,
IQR 0.17). There was no significant difference in
the concentrations of nitrate present in the plasma of
RA patients compared with the plasma of healthy
controls.
Analyses of correlations between the concentra-
tions of calreticulin and those of nitrite or nitrate
present in the plasma and synovial fluid of RA patients
were performed using Spearman’s rank correlation co-
efficient analyses (at a level of significance of P  0.05),
but no significant correlations were found (results not
shown).
Inhibition of FasL-induced early apoptosis by
binding of calreticulin to FasL. Calreticulin binding to
FasL has been observed previously (10), and this was
confirmed by our results on ELISA (Figure 5A). The
Figure 5. Demonstration of calreticulin (CRT) binding to FasL, and inhibition of FasL-induced
apoptosis by calreticulin in Jurkat T cells. A, Calreticulin (10 g/ml) was immobilized on microtiter
plates and incubated with FasL (0, 1, and 2 g/ml). FasL binding to calreticulin was detected using an
anti-FasL antibody followed by a horseradish peroxidase–conjugated goat anti-rabbit antibody (binding
details are described in Patients and Methods). Bars show the mean and SD.   P  0.05 versus no
FasL. B–E, The percentage of living (B), early apoptotic (C), late apoptotic (D), and necrotic (E) Jurkat
T cells in the presence of increasing concentrations of calreticulin (0–16 ng/ml), with or without FasL,
was detected by flow cytometry. Where added, the concentration of FasL was 0.78 nM. Bars show the
mean and SD normalized data from 4 individual experiments performed in triplicate. In cases where no
error bars are visible, the SD is smaller than the data point. The baseline level of living cells after
treatment with 0.78 nM FasL was 37.9	 16.2%.  P 0.05 versus no calreticulin. Triangles represent
FasL and calreticulin treatment; squares represent calreticulin treatment alone.
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normalized results showed that calreticulin bound to
FasL in a dose-dependent manner.
Having confirmed that FasL binds to calreticulin,
we investigated whether calreticulin could inhibit FasL-
induced apoptosis. The addition of 1 ng/ml (0.02 nM)
calreticulin along with 0.78 nM FasL had no significant
effect on the level of living Jurkat T cells as compared
with FasL treatment alone (Figure 5B). However, coin-
cubation of calreticulin at a concentration of 2, 4, 8, or
16 ng/ml (0.04, 0.08, 0.16, or 0.34 nM, respectively) with
0.78 nM FasL significantly inhibited FasL-mediated ap-
optosis of Jurkat cells as compared with FasL treatment
alone. The addition of calreticulin alone (1–16 ng/ml;
0.02–0.34 nM) had no significant effect on Jurkat cell
death (Figure 5B). Furthermore, the addition of calre-
ticulin (2, 4, 8, or 16 ng/ml; 0.04–0.34 nM) with 0.78 nM
FasL significantly decreased the number of early apo-
ptotic cells by between 10% and 20% as compared with
FasL treatment alone (Figure 5C). The treatment of
Jurkat T cells with FasL and a range of concentrations of
calreticulin (1–16 ng/ml; 0.02–0.34 nM) or calreticulin
alone (1–16 ng/ml) had no significant effect on the
percentage of late apoptotic cells (Figure 5D) or ne-
crotic cells (Figure 5E). These data indicate that prein-
cubation of calreticulin with FasL is able to significantly
inhibit the early apoptosis induced by FasL alone.
After demonstrating that binding of calreticulin
to FasL could inhibit FasL-mediated apoptosis of Jurkat
cells, we determined whether a specific antibody against
calreticulin could block the calreticulin-mediated inhibi-
tion of FasL-induced apoptosis. As shown in Figures
6A–D, there was a concentration-dependent blocking of
calreticulin inhibition of FasL-mediated apoptosis by
anticalreticulin. This inhibition became statistically sig-
nificant when 25 nM anticalreticulin was preincubated
with 16 ng/ml (0.34 nM) calreticulin.
Figure 6. Anticalreticulin (anti-CRT) blocking of calreticulin inhibition of FasL-mediated apo-
ptosis. Jurkat cells were treated with 0.78 nM FasL in the presence of calreticulin (16 ng/ml; 0.34
nM final concentration), which resulted in 48% of cells surviving (results normalized to 100%).
Calreticulin (16 ng/ml; 0.34 nM final concentration) was coincubated with a range of anti-CRT IgG
concentrations (0–25 nM) and then incubated with 0.78 nM FasL, before addition to the Jurkat T
cells (1  106). A significant reduction in living cells was observed following incubation with FasL,
calreticulin, and 25 nM anti-CRT (A). Simultaneously, an increase in early apoptosis (B) and late
apoptosis (C) of Jurkat cells occurred in the presence of 25 nM anti-CRT and 16 ng/ml (0.34 nM)
calreticulin. Necrotic cell death was unaffected (D). Bars show the mean 	 SD results from 3
individual experiments performed in triplicate.  P 0.05 versus cultures with 0.78 nM FasL and
16 ng/ml calreticulin, by Mann-Whitney U test.
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DISCUSSION
RA is an autoimmune disease that is character-
ized by the presence of autoreactive T cells in the
peripheral blood and synovial joints (35). Synovial T
cells orchestrate a wide array of clinical sequelae, includ-
ing chronic inflammation, cartilage damage, and bone
erosion (36). It has been hypothesized that dysfunctional
or resistant apoptosis of T cells could be integral to the
pathogenesis of RA, promoting the progressive destruc-
tion of joint and cartilage structures (1,3,7). The trigger
for T cell resistance is unclear, but an impaired Fas
signaling pathway has been suggested to be involved in
defective T cell apoptosis (6).
Calreticulin is known to bind to a number of
immunologically important proteins, such as C1q, and
collectins (15). It recently has been demonstrated that
calreticulin binds to apoptotic regulatory proteins such
as TRAIL and FasL (10). In the present study, we
confirmed the findings of Duus and coworkers (10) that
demonstrate that calreticulin binds to FasL. In view of
the evidence of an apoptosis-resistant population of T
cells in the synovial fluid of RA patients and the fact that
FasL binding to Fas on the surface of cells is an
important mechanism of noninflammatory cell death,
we sought to determine whether the calreticulin–FasL
interaction impeded FasL-mediated apoptosis of T cells.
We demonstrated that coincubation of FasL with vary-
ing concentrations of calreticulin (0–16 ng/ml) reduced
Jurkat T cell death by up to 20% compared with the level
of cell death with FasL alone. The significant reductions
in FasL-mediated apoptosis occurred with calreticulin
concentrations well within the range of values that were
observed in the plasma and synovial fluid of RA patients
(3–40 ng/ml).
The mechanism of calreticulin release or secre-
tion from cells is uncertain. Release may be via the
secretory pathway (37) or by an unconventional mecha-
nism (38). Our own findings suggest that calreticulin
release is regulated by a NO-dependent mechanism
(39). Previously, we demonstrated that calreticulin is
released from activated neutrophils by the process of
necrosis (15). In view of this, we measured the LDH
concentrations in our patient groups and compared the
values with extracellular calreticulin concentrations. We
observed a significant increase in the median LDH
activity in the plasma of RA patients compared with that
in the plasma of healthy controls (Figure 3); this could
possibly be attributed to the increase in liver toxicity
transiently observed in RA patients who were receiving
treatment with methotrexate (40). A further significant
increase in median LDH activity was observed in the
synovial fluid samples from RA patients as compared
with matched plasma samples from the same patients,
suggesting that the increased LDH activity was being
produced locally in the synovial joint. However, there
was no significant correlation between LDH activity and
calreticulin concentrations in the RA samples in which
calreticulin levels were significantly increased as com-
pared with those in the healthy and disease control
groups (results not shown). This indicates that calreticu-
lin levels in the synovial fluid of RA patients are likely to
be released through non-necrotic mechanisms.
Our observation of a correlation between calre-
ticulin production and disease activity provides further
evidence for a possible role of calreticulin in RA. A
proposed ligand for calreticulin on the surface of lym-
phocytes in the vast majority of RA patients is the
shared epitope (18). It has been hypothesized that
calreticulin binds to this 5–amino acid sequence motif in
the third allelic hypervariable region of the HLA–DR
-chain. This binding leads to increased NO production
and promotes immune dysregulation (41).
In view of these observations, we measured the
concentrations of the stable end products of NO pro-
duction, namely, nitrate and nitrite, in both the plasma
and synovial fluid samples from disease and control
groups. A significant increase in the level of nitrite in the
plasma and synovial fluid of RA patients compared with
that from patients with PsA was found in this study.
Earlier studies also demonstrated increased concentra-
tions of nitrite and nitrate in the plasma and synovial
fluid of RA patients (42–45). There was no association
between the concentrations of calreticulin and those of
nitrite or nitrate in the plasma or synovial fluid of RA
patients (results not shown). A possible reason for this
lack of association is that membrane-bound and intra-
cellular calreticulin is involved in the increased produc-
tion of NO. In the present study, we only measured the
levels of extracellular calreticulin present in the RA
patients’ plasma and synovial fluid. A second possible
reason for the lack of correlation between calreticulin
concentrations and nitrite and nitrate concentrations is
that NO is a reactive molecule that can form a number
of metabolites other than nitrite and nitrate. Therefore,
by limiting the measurements to nitrite and nitrate, we
were not measuring the total NO production within the
RA patients’ plasma or synovial fluid (46).
The present results suggest an additional role for
extracellular calreticulin in apoptosis. Previous studies
have determined that extracellular calreticulin–C1q in-
teractions mediated the recognition and clearance of
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apoptotic blebs via the C1q/calreticulin/CD91 apoptotic
pathway (47), which is impaired in some autoimmune
diseases (48). Thus, extracellular calreticulin may have a
number of roles to play during apoptosis, by inhibiting
FasL-mediated apoptosis, but may aid in the clearance
of apoptotic debris once cells have undergone apoptosis.
In conclusion, calreticulin was shown to bind to
FasL and inhibit Jurkat T cell death. In other auto-
immune diseases, anticalreticulin autoantibodies are
prevalent. This is not the case in RA. This raises the
possibility that autoantibodies against calreticulin may
neutralize the ability of calreticulin to inhibit FasL/Fas-
mediated cell death. In addition, other mechanisms of
inhibition of FasL-mediated cell death are also known to
occur (for review, see ref. 49), involving overexpression
of antiapoptotic molecules. For example, overactivation
of survival signals (e.g., sphingosine 1-phosphate) can
inhibit JNK expression and suppress activation of G
protein–coupled proapoptotic executioner caspases
(50). Infiltrating T cells, within the synovial lining layer,
express the antiapoptotic protein Bcl-2, the levels of
which are correlated with T cell resistance to Fas
apoptosis (51). Overall, this suggests that multiple path-
ways contribute to the resistance of lymphocyte apopto-
tic death during the pathogenesis of joint destruction in
patients with RA.
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